{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:59:20Z","timestamp":1781193560110,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.03.025","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:10:06Z","timestamp":1778717406000},"page":"604-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of a Tacrolimus Lipid Suspension Enema in Mild-to-Moderate Ulcerative Colitis: A Multicenter, Prospective, Double-Blind, Phase II Randomized Controlled Trial"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-0093","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok R.","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanj","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.025_bib0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12950-020-00246-4","article-title":"Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies","volume":"17","author":"Kaur","year":"2020","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0003","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current pharmacotherapeutic options for the treatment of ulcerative colitis","volume":"11","author":"Ferretti","year":"2022","journal-title":"J Clin Med"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2026.03.025_bib0004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000504092","article-title":"Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update","volume":"101","author":"Burri","year":"2020","journal-title":"Digestion"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0006","first-page":"21","article-title":"A comprehensive review of topical therapies for distal ulcerative colitis","volume":"16","author":"Cohen","year":"2020","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2011.04800.x","article-title":"Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis\u2014additional results from two controlled studies","volume":"34","author":"Sandborn","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.crohns.2013.08.007","article-title":"Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life","volume":"8","author":"Probert","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0009","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.3390\/jcm12216929","article-title":"Treatment of patients with mild to moderate ulcerative colitis: a Middle East expert consensus","volume":"12","author":"Awadhi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0011","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ueg2.12283","article-title":"Definition of mild to moderate ulcerative colitis in clinical trials: a systematic literature review","volume":"10","author":"Caron","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0012","first-page":"893","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"Karagozian","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0013","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1365-2036.2011.04619.x","article-title":"Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis","volume":"33","author":"Harris","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2026.03.025_bib0014","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","author":"Sutherland","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ghep.ghep_17_23","article-title":"Management of ulcerative colitis: a review of Indian literature","volume":"3","author":"Rajendran","year":"2023","journal-title":"Gastroenterol Hepatol Endosc Pract"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0016","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1365-2036.2007.03334.x","article-title":"Review article: the management of steroid dependency in ulcerative colitis","volume":"26","author":"Bianchi Porro","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5217\/ir.2015.13.3.219","article-title":"Tacrolimus for the treatment of ulcerative colitis","volume":"13","author":"Matsuoka","year":"2015","journal-title":"Intest Res"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0018","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ibd.20644","article-title":"Local application of tacrolimus in distal colitis: feasible and safe","volume":"15","author":"van Dieren","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0019","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/ajt.13309","article-title":"Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation","volume":"15","author":"Sikma","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","article-title":"Nanostructured lipid carrier co-delivering tacrolimus and TNF-\u03b1 siRNA as an innovate approach to psoriasis","volume":"10","author":"Viegas","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0021","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/pharmaceutics15020656","article-title":"Current advances in lipid nanosystems intended for topical and transdermal drug delivery applications","volume":"15","author":"Akombaetwa","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0022","article-title":"Lipid-based drug delivery systems","volume":"2014","author":"Shrestha","year":"2014","journal-title":"J Pharm (Cairo)"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0023","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2036.2008.03841.x","article-title":"Rectal tacrolimus in the treatment of resistant ulcerative proctitis","volume":"28","author":"Lawrance","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0024","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2017.02.027","article-title":"Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis","volume":"15","author":"Lawrance","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0025","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/194324","article-title":"Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis","volume":"2011","author":"Bamba","year":"2011","journal-title":"ISRN Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0026","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1248\/bpb.27.1480","article-title":"Increased bioavailability of tacrolimus after rectal administration in rats","volume":"27","author":"Sakai","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000493979","article-title":"Tacrolimus suppositories in therapy-resistant ulcerative proctitis","volume":"3","author":"Jaeger","year":"2019","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0028","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/jgh3.12280","article-title":"Simple water-based tacrolimus enemas for refractory proctitis","volume":"4","author":"Fehily","year":"2019","journal-title":"JGH Open"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0029","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14740338.6.5.479","article-title":"The use of tacrolimus in the treatment of inflammatory bowel disease","volume":"6","author":"Chow","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0030","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.3390\/jcm13185518","article-title":"The role of topical tacrolimus in the management of inflammatory bowel disease: a comprehensive review","volume":"13","author":"Khayatan","year":"2024","journal-title":"J Clin Med"},{"issue":"Pt A","key":"10.1016\/j.clinthera.2026.03.025_bib0031","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jcis.2022.09.146","article-title":"Efficient local delivery of FK506 using blocking patches in psoriasis","volume":"630","author":"Zhao","year":"2023","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.clinthera.2026.03.025_bib0032","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00007.x","article-title":"Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients","volume":"48","author":"B\u00f6ttiger","year":"1999","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:17:29Z","timestamp":1781191049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0149291826001013"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.025","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of a Tacrolimus Lipid Suspension Enema in Mild-to-Moderate Ulcerative Colitis: A Multicenter, Prospective, Double-Blind, Phase II Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}